Literature DB >> 29067509

Transvenous Retrograde Thoracic Ductography: Initial Experience with 13 Consecutive Cases.

Shuji Kariya1, Miyuki Nakatani2, Yutaka Ueno2, Asami Yoshida2, Yasuyuki Ono2, Takuji Maruyama2, Atsushi Komemushi2, Noboru Tanigawa2.   

Abstract

PURPOSE: To report the feasibility and findings of transvenous retrograde thoracic duct cannulation.
MATERIALS AND METHODS: The subjects were 13 patients who had undergone retrograde transvenous thoracic ductography. Despite conservative treatment, all required drainage for chylothorax, chylous ascites, or a chylous pericardial effusion. Lymphangiography was performed, and the junction of the thoracic duct with the vein was identified. A microcatheter was inserted into the thoracic duct retrogradely via the junction with the vein.
RESULTS: The catheter could be inserted to the cervical part, thoracic part, and cisterna chyli in 12 (92.3%), nine (69.2%), and six (46.2%) patients, respectively. Successful transvenous thoracic ductography was performed in eight patients (61.5%). The cervical part of the thoracic duct was branched into a plexiform configuration beyond which the microcatheter could not be advanced to reach the thoracic part in three unsuccessful cases. The success rate of transvenous thoracic ductography was significantly higher with the simple type (80%) than with the plexiform type (0%; p = 0.035). No extravasation of contrast agent was seen in the eight patients with successful thoracic ductography. Thoracic duct embolization was performed in one patient with a chylous pericardial effusion in whom myriad lymph ducts connecting to the hilar and pericardial regions from the thoracic duct were found, and drainage was unnecessary.
CONCLUSION: Transvenous retrograde thoracic ductography was successful in only eight of 13 patients (61.5%), but when the cervical part was the simple type, it was successful in eight of 10 patients (80%).

Entities:  

Keywords:  Chylous effusion; Leakage; Lymphangiography; Thoracic duct; Transvenous thoracic ductography

Mesh:

Year:  2017        PMID: 29067509     DOI: 10.1007/s00270-017-1814-y

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.740


  7 in total

Review 1.  Complications during Lymphangiography and Lymphatic Interventions.

Authors:  Bill S Majdalany; Mamadou L Sanogo; Waleska M Pabon-Ramos; Kyle A Wilson; Abhishek K Goswami; Nima Kokabi; Minhaj S Khaja
Journal:  Semin Intervent Radiol       Date:  2020-07-31       Impact factor: 1.513

Review 2.  Lymphatic Imaging: Current Noninvasive and Invasive Techniques.

Authors:  Fides R Schwartz; Olga James; Phillip H Kuo; Marlys H Witte; Lynne M Koweek; Waleska M Pabon-Ramos
Journal:  Semin Intervent Radiol       Date:  2020-07-31       Impact factor: 1.513

Review 3.  Chylous Ascites and Lymphoceles: Evaluation and Interventions.

Authors:  Ernesto Santos; Amgad M Moussa
Journal:  Semin Intervent Radiol       Date:  2020-07-31       Impact factor: 1.513

4.  Retrograde transvenous selective lymphatic duct embolization in post donor nephrectomy chylous ascites.

Authors:  Shekhar Kalia; Amey Narkhede; Ajit Kumar Yadav; Anil Kumar Bhalla; Arun Gupta
Journal:  CEN Case Rep       Date:  2021-07-04

Review 5.  Thoracic Trauma, Nonaortic Injuries.

Authors:  Kai A Jones; Shirin Sadri; Noor Ahmad; Joseph R Weintraub; Stephen P Reis
Journal:  Semin Intervent Radiol       Date:  2021-04-15       Impact factor: 1.513

6.  Anatomy of the lymphovenous valve of the thoracic duct in humans.

Authors:  Lomani Archibald O'Hagan; John Albert Windsor; Anthony Ronald John Phillips; Maxim Itkin; Peter Spencer Russell; Seyed Ali Mirjalili
Journal:  J Anat       Date:  2020-02-27       Impact factor: 2.921

7.  Lymphatic imaging and intervention for chylothorax following thoracic aortic surgery.

Authors:  Cheng Shi Chen; Jong Woo Kim; Ji Hoon Shin; Hyun Jung Koo; Joon Bum Kim; Hai-Liang Li; Se Hwan Kwon; Alrashidi Ibrahim; Almoaiad A Alhazemi; Hee Ho Chu
Journal:  Medicine (Baltimore)       Date:  2020-08-21       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.